YIA25-001: Molecular Residual Disease (MRD) Guided Adjuvant Therapy In Renal Cell Carcinoma (RCC) - The MRD GATE RCC Study. | UCSF Helen Diller Family Comprehensive Cancer Center

YIA25-001: Molecular Residual Disease (MRD) Guided Adjuvant Therapy In Renal Cell Carcinoma (RCC) - The MRD GATE RCC Study.

Author List

Basu A, Sidhom F, Hwang C, Ferguson J, Peyton C, Bae S, Kilari D, Desai A, Rais-Bahrami S

Publication

Publication ID (Profile URL)

https://researcherprofiles.org/profile/679825342

Publication Year

2025

PubMed ID

40154405